NAD+ injections, IV drips and oral precursors: what the research shows

Injection, IV, sublingual or oral precursor

NAD+ is sold in four different formats that are not interchangeable, and most of the confusion online comes from comparing results across them as if they were the same thing.

• Intravenous NAD+ infusions are what clinics offer, typically 250–1,000 mg over several hours. Infusing quickly is what produces the chest tightness and nausea people report, which is why the drip is slowed.
• Subcutaneous or intramuscular NAD+ injection is the at-home format, usually compounded. There is no approved product and no published human pharmacokinetic study of this route.
• Sublingual tablets and sprays aim to bypass digestion. Absorption data for the intact molecule is limited.
• Oral precursors — nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) — are the formats with actual randomized human trials behind them, and they raise blood NAD+ measurably.
• Whether raising the NAD+ number produces a clinical benefit is the open question. Trials so far show the biomarker moves; outcome results are mixed and mostly small.

What has been shown in people

Separate the biomarker from the benefit. The first is well documented; the second is not settled.

• Nicotinamide riboside raises whole-blood NAD+ in randomized trials, in a dose-dependent way, and has been tolerated at 1,000–2,000 mg per day in trials of several weeks to months.
• NMN trials report increased blood NAD+ and some improvements in walking endurance and fatigue scores in older adults, with small sample sizes.
• For intravenous NAD+ itself, published human data is thin: a small pharmacokinetic study showed the infused molecule is metabolized rather than taken up intact in the way clinics often describe.
• No randomized trial supports NAD+ injections or infusions for anti-aging, addiction recovery or chronic fatigue, all of which are marketed uses.
• The FDA has moved to restrict NAD+ as a compounding bulk substance, which affects availability of compounded injectable product in the United States.

Cost, side effects and what clinics charge

This is usually what decides the question, and it is rarely laid out next to the evidence.

• IV sessions are commonly priced in the hundreds of dollars each, and protocols often propose a series. Oral precursors cost a fraction of that per month.
• Infusion-rate side effects — chest pressure, nausea, cramping, flushing — are common and resolve when the rate is reduced.
• Injection-site reactions are the usual complaint with subcutaneous use.
• Compounded injectables carry the standard risks: no pre-market review, variable content, and sterility dependent entirely on the pharmacy.
• Nobody has established a dose-response curve for any of these routes in humans, so protocols vary between clinics without an evidential basis for the difference.

References

• Chronic nicotinamide riboside supplementation is well tolerated and elevates NAD+ (Martens CR, et al., Nature Communications)
• Effect of 12-week NMN supplementation on walking endurance in older adults
• Pharmacokinetics of intravenous NAD+ in humans (Grant R, et al.)
• FDA — Bulk drug substances under evaluation for compounding